Protalix BioTherapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

Author's Avatar
Oct 29, 2020
Article's Main Image

Announced FDA acceptance of BLA filing of PRX-102 for the treatment of Fabry disease

Top-line data from the BRIGHT study expected by end of first quarter, 2021

Management to host conference call and live webcast today, October 29, at 8:30 am ET

PR Newswire